
AKASA, the preeminent supplier of generative AI options for the healthcare income cycle, has been acknowledged by AIM Analysis as one of many “Quickest Rising GenAI Startups to Watch within the U.S. 2024.”
This text initially appeared on AKASA’s web site.
AIM Analysis, a premier AI and knowledge science market analysis agency, recognized AKASA as a standout firm because of its groundbreaking options that merge superior AI expertise with the complexities of healthcare operations.
This revered distinction highlights AKASA’s progressive use of generative AI (GenAI) to streamline income cycle administration for healthcare suppliers, bettering income yield and enhancing operational effectivity. AKASA is one in every of solely two corporations on the listing that serve the healthcare trade.
“We’re honored to be acknowledged for our work in GenAI,” mentioned Malinka Walaliyadde, CEO and co-founder of AKASA. “It’s a testomony to the dedication and innovation of our crew. We’re utilizing the perfect expertise out there to unravel essentially the most complicated issues of the income cycle.” Click on right here to proceed>>
Information From Our Companions